Abstract
We studied 12 children (11 F,1M) with idiopathic short stature, aged 11.5±0.35 years (9.6-12.7 yr), height age 9.9±0.21yr(9.0-11.2yr),bone age 11.17±0.24yr(10.0-13.0yr) and height standard deviation for age -1.8 ± 0.33 SD. All were pubertal at start (3 Tanner II, 9 Tanner III) and had a short final height prediction according to the Bayley Pinneau method:148.84±1.05 cm (142.59-153.56 cm, 11F) and 162.1 cm(1M)and a growth velocity (GV) of 5.76 ± 0.49 cm/yr (4.0-10.2 cm/yr). Puberty was temporarily blocked with a long-acting GnGH analog (DTrp6-LHRH, Decapeptyl), 60 ug/Kg/month,im). Hormonal data were obtained before and after 6 months (m) of therapy and auxological data after 6m, 12m and 18m. The 125 I-hGH was incubated with 150 ul of serum, bound and free GH were separated by gel filtration, and the ratio of bound (bound+free) labelled GH was considered as GHBP. Pretreatment GHBP (25.94±1.68%) was not different from the control group (27.0±0.8%)and did not change after 6mo of therapy (26.7±2.3%). There was a significant decrease in peack GH levels the ornithine stimulation test (p<0.002) and during sleep (p<0.002) after 6m of therapy. The bone age maturation was already slower by 6mo (p<0.002) and more significantly by 18mo (p<0.001). The GV diminished by 12m(p< 0.05) and 18m (p<0.005). The improvement in final height prediction was 2.23±0.91(p<0.05)by 6m and 3.28±0.78 cm(p<0.002) by 18m of therapy. A follow-up to final height is necessary to confirm the possible beneficial effects of this therapy.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oliveira, S., Donnadieu, M. & Chaussain, J. 21 THERAPY OF IDIOPATHIC SHORT STATURE WITH LONG-ACTING GnRH ANALOG; EFFECTS ON GROWTH HORNOE (GH), GROWTH HORMONE-BINDING PROTEIN (GHBP) AND FINAL HEIGHT PREDICTION. Pediatr Res 36, 681 (1994). https://doi.org/10.1203/00006450-199411000-00079
Issue Date:
DOI: https://doi.org/10.1203/00006450-199411000-00079